Clinical Trial Update: A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a CD19-targeted CAR-T therapy for B-cell lymphoproliferative disorders has completed, assessing tolerability, safety, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Anti-CD19 CAR-T therapy (Phase 1/2 trial) (CD19-targeted chimeric antigen receptor T-cell)

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1, Phase 2 | Status: COMPLETED